STOCK TITAN

[8-K] Medpace Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Medpace Holdings, Inc. furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference.

The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" under the Exchange Act. MEDP’s common stock trades on the NASDAQ Global Select Market.

Medpace Holdings, Inc. ha inviato un 8-K annunciando la pubblicazione di un comunicato stampa con i risultati finanziari per i tre e nove mesi terminati il 30 settembre 2025. Il comunicato stampa è incluso come Exhibit 99.1 ed è incorporato per riferimento.

L'azienda afferma che le informazioni nell'Item 2.02, incluso l'Exhibit 99.1, sono fornite e non devono essere considerate come “depositate” ai sensi del Securities Exchange Act. Le azioni ordinarie MEDP sono quotate sul NASDAQ Global Select Market.

Medpace Holdings, Inc. presentó un Formulario 8-K anunciando que emitió un comunicado de prensa con los resultados financieros para los tres y nueve meses terminados el 30 de septiembre de 2025. El comunicado de prensa se incluye como Exhibit 99.1 y se incorpora por referencia.

La empresa indica que la información en el Ítem 2.02, incluido el Exhibit 99.1, se está presentando y no debe entenderse como “presentada” conforme a la Ley de Intercambio. Las acciones comunes de MEDP cotizan en el NASDAQ Global Select Market.

Medpace Holdings, Inc. 8-K를 제출하여 2025년 9월 30일로 종료된 3개월 및 9개월의 재무 실적에 대한 보도자료를 발표했다고 공시했습니다. 보도자료는 Exhibit 99.1로 포함되며 참조로 편입됩니다.

회사는 Item 2.02의 정보(포함된 Exhibit 99.1)가 제출되고 “제출로 간주되지 않는다”라는 내용이라고 명시합니다. MEDP의 보통주는 NASDAQ Global Select Market에서 거래됩니다.

Medpace Holdings, Inc. a déposé un 8-K annonçant la publication d’un communiqué de presse présentant les résultats financiers pour les trois et neuf mois se terminant le 30 septembre 2025. Le communiqué de presse est inclus en tant que Exhibit 99.1 et est incorporé par référence.

La société indique que les informations contenues dans l’Item 2.02, y compris l’Exhibit 99.1, sont fournies et ne doivent pas être considérées comme « déposées » en vertu de la loi sur les échanges. L’action ordinaire de MEDP est négociée sur le NASDAQ Global Select Market.

Medpace Holdings, Inc. hat eine 8-K vorgelegt, in der bekannt gegeben wird, dass ein Pressemitteilungs mit den Finanzergebnissen für die drei und neun Monate zum 30. September 2025 veröffentlicht wurde. Die Pressemitteilung ist als Exhibit 99.1 enthalten und durch Verweis integriert.

Das Unternehmen erklärt, dass die Informationen in Item 2.02, einschließlich Exhibit 99.1, wird bereitgestellt und darf nicht als „eingereicht“ im Sinne des Exchange Act betrachtet werden. Die Stammaktie von MEDP wird an der NASDAQ Global Select Market gehandelt.

Medpace Holdings, Inc. قدمت نموذج 8-K معلنة أن بياناً صحفياً يوضح النتائج المالية للفترات المنتهية في 30 سبتمبر 2025 للثلاثة والتسعة أشهر. يُدرج البيان الصحفي كـ Exhibit 99.1 ويُدمج بالإحالة.

تقول الشركة إن المعلومات الواردة في البند 2.02، بما في ذلك Exhibit 99.1، يتم تقديمها ولا تعتبر “مُقدمة” وفقاً لقانون التبادل. أسهم MEDP العادية مدرجة في سوق NASDAQ Global Select Market.

Medpace Holdings, Inc. 已提交一份8-K,宣布就截至2025年9月30日的三个月及九个月的财务业绩发布了新闻稿。该新闻稿作为Exhibit 99.1包含在内,并通过引用并入。

公司表示,信息在项2.02中,包括Exhibit 99.1,被提供且不得被视为“已提交”,依据交易法。MEDP的普通股在纳斯达克全球精选市场交易。

Positive
  • None.
Negative
  • None.

Medpace Holdings, Inc. ha inviato un 8-K annunciando la pubblicazione di un comunicato stampa con i risultati finanziari per i tre e nove mesi terminati il 30 settembre 2025. Il comunicato stampa è incluso come Exhibit 99.1 ed è incorporato per riferimento.

L'azienda afferma che le informazioni nell'Item 2.02, incluso l'Exhibit 99.1, sono fornite e non devono essere considerate come “depositate” ai sensi del Securities Exchange Act. Le azioni ordinarie MEDP sono quotate sul NASDAQ Global Select Market.

Medpace Holdings, Inc. presentó un Formulario 8-K anunciando que emitió un comunicado de prensa con los resultados financieros para los tres y nueve meses terminados el 30 de septiembre de 2025. El comunicado de prensa se incluye como Exhibit 99.1 y se incorpora por referencia.

La empresa indica que la información en el Ítem 2.02, incluido el Exhibit 99.1, se está presentando y no debe entenderse como “presentada” conforme a la Ley de Intercambio. Las acciones comunes de MEDP cotizan en el NASDAQ Global Select Market.

Medpace Holdings, Inc. 8-K를 제출하여 2025년 9월 30일로 종료된 3개월 및 9개월의 재무 실적에 대한 보도자료를 발표했다고 공시했습니다. 보도자료는 Exhibit 99.1로 포함되며 참조로 편입됩니다.

회사는 Item 2.02의 정보(포함된 Exhibit 99.1)가 제출되고 “제출로 간주되지 않는다”라는 내용이라고 명시합니다. MEDP의 보통주는 NASDAQ Global Select Market에서 거래됩니다.

Medpace Holdings, Inc. a déposé un 8-K annonçant la publication d’un communiqué de presse présentant les résultats financiers pour les trois et neuf mois se terminant le 30 septembre 2025. Le communiqué de presse est inclus en tant que Exhibit 99.1 et est incorporé par référence.

La société indique que les informations contenues dans l’Item 2.02, y compris l’Exhibit 99.1, sont fournies et ne doivent pas être considérées comme « déposées » en vertu de la loi sur les échanges. L’action ordinaire de MEDP est négociée sur le NASDAQ Global Select Market.

Medpace Holdings, Inc. hat eine 8-K vorgelegt, in der bekannt gegeben wird, dass ein Pressemitteilungs mit den Finanzergebnissen für die drei und neun Monate zum 30. September 2025 veröffentlicht wurde. Die Pressemitteilung ist als Exhibit 99.1 enthalten und durch Verweis integriert.

Das Unternehmen erklärt, dass die Informationen in Item 2.02, einschließlich Exhibit 99.1, wird bereitgestellt und darf nicht als „eingereicht“ im Sinne des Exchange Act betrachtet werden. Die Stammaktie von MEDP wird an der NASDAQ Global Select Market gehandelt.

FALSE000166839700016683972025-10-222025-10-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
______________________________________________________
FORM 8-K
______________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 22, 2025
______________________________________________________
Medpace Holdings, Inc.
(Exact name of Registrant as Specified in Its Charter)
______________________________________________________
Delaware001-3785632-0434904
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)(IRS Employer
Identification No.)
5375 Medpace Way
Cincinnati, Ohio
45227
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: 513 579-9911
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
______________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)
Name of each exchange on which registered
Common Stock $0.01 par valueMEDPNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



Item 2.02 Results of Operations and Financial Condition.
On October 22, 2025, the Company issued a press release announcing its financial results for the three and nine months ended September 30, 2025. The full text of the press release was posted on the Company’s internet website and is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information contained in, or incorporated into, Item 2.02, including the press release attached as Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.

Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
Press release dated October 22, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
MEDPACE HOLDINGS, INC.
Date:October 22, 2025By:/s/ Kevin M. Brady
Kevin M. Brady, Chief Financial Officer

FAQ

What did Medpace (MEDP) announce in this 8-K?

Medpace furnished a press release with financial results for the three and nine months ended September 30, 2025, attached as Exhibit 99.1.

Which period does MEDP’s update cover?

The press release covers the three and nine months ended September 30, 2025.

Is the information considered filed or furnished?

The information in Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" under the Exchange Act.

Where can I find the detailed results?

Detailed results are in Exhibit 99.1 (press release) referenced in the 8-K.

What is Medpace’s trading symbol and exchange?

Medpace trades under MEDP on the NASDAQ Global Select Market.

When was the press release dated?

The press release is dated October 22, 2025.
Medpace Holdings

NASDAQ:MEDP

MEDP Rankings

MEDP Latest News

MEDP Latest SEC Filings

MEDP Stock Data

15.33B
22.27M
20.7%
96.78%
8.02%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
CINCINNATI